Lazard Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Lazard Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-141,208	Closed	-$458K	–	1843
2019 Q4	$458K	Buy	+141,208	New	+$410K	﹤0.01%	819
2016 Q2	–	Sell	-4,043	Closed	-$13K	–	1157
2016 Q1	$13K	Buy	+4,043	New	+$12.6K	﹤0.01%	941
2015 Q2	–	Sell	-282,653	Closed	-$1.99M	–	1232
2015 Q1	$1.99M	Sell	282,653 -14,367	-5%	-$104K	﹤0.01%	638
2014 Q4	$2.29M	Sell	297,020 -60,000	-17%	-$475K	﹤0.01%	643
2014 Q3	$2.67M	Buy	357,020 +51,420	+17%	+$477K	0.01%	588
2014 Q2	$2.96M	Sell	305,600 -63,894	-17%	-$569K	0.01%	592
2014 Q1	$3.07M	Buy	369,494 +274,415	+289%	+$2.35M	0.01%	546
2013 Q4	$802K	Buy	95,079 +45,079	+90%	+$380K	﹤0.01%	726
2013 Q3	$398K	Buy	+50,000	New	+$402K	﹤0.01%	751

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Lazard Asset Management's PDLI Position: Q1 2020 in Review

Lazard Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 141,208 shares — an estimated $458K sold.

Lazard Asset Management first reported a position in PDLI in Q3 2013 and held it in 9 quarters. The position peaked at $3.07M in Q1 2014. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Lazard Asset Management reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Lazard Asset Management sold 141,208 PDL BioPharma, Inc. shares in Q1 2020, an estimated $458K.
Lazard Asset Management first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 9 quarters.
Lazard Asset Management's PDL BioPharma, Inc. position peaked at $3.07M in Q1 2014.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Lazard Asset Management's 13F filing for Q1 2020, filed 14 May 2020.